Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group Holdings Ltd granted Australian medicinal cannabis manufacturing licence

AusCann was established to provide high quality, cost effective cannabinoid medicines.
AusCann's growing facility in Chile

AusCann Group Holdings Ltd (ASX:AC8) has been granted an Australian medicinal cannabis manufacturing licence by the Office of Drug Control.

The licence enables the manufacture and supply of cannabinoid medicines, completing the supply chain for the company.

AusCann is now strongly positioned to be a leading supplier of Australian cannabinoid medicines for Australian patients, and potential export in the future.

Elaine Darby, managing director, commented:

"AusCann was established to provide high quality, cost effective cannabinoid medicines for Australian patients.

"Securing both a cultivation and a manufacturing licence will enable us to achieve this aim and demonstrates our leadership position in the industry.

"In preparation for the supply of Australian produced medicines, AusCann has been actively engaged with the medical community through its educational and medical outreach program.

"AusCann has made excellent progress raising awareness and support amongst the medical community and is well positioned to become the supplier of choice for Australian patients."

History of licenses

Today's approval follows the Australian cultivation licences that have been granted for the company’s site in Western Australia in May this year, and in Tasmania through its strategic partnership with Tasmanian Alkaloids last month.

AusCann and its strategic partner, Tasmanian Alkaloids, are awaiting the outcome of a further manufacturing licence application for the proposed operations in Tasmania.

Operating since 1976, Tasmanian Alkaloids produces circa 40% of the world’s alkaloid raw material crop in Tasmania.

It boasts a modern manufacturing facility, which is fully compliant with Good Manufacturing Practice standards.

Tasmanian Alkaloids has established relationships with many of the world’s leading pharmaceutical companies.

Mutually beneficially relationship

Studies have shown that the inclusion of medicinal cannabis into existing pain management regimes involving opiates resulted in an improvement in pain management and quality of life outcomes, and less adverse side effects.

Cannabinoids and opioids share several pharmacologic properties and may act synergistically in pain treatment.

As such, both parties look forward to also working together to develop novel therapeutic products for the relief of chronic pain.

Furthermore, while this strategic partnership builds, AusCann is able to leverage its other partnership with Canopy Growth Corporation in the short term.

AusCann is able to import medicines from its partner Canopy Growth Corporation, North America’s largest producer of medicinal cannabis.

Momentum in medical cannabis

The positive momentum in the medical cannabis sector continues to grow with a comprehensive report by the U.S. National Academies of Science Engineering Medicine released earlier this year confirming that there is substantial and conclusive evidence for the use of medicinal cannabis in the treatment of chronic pain symptoms.

The need for chronic pain control in Australia is substantial and represents a market of over 3 million patients.

Share price reaction

AusCann shares have jumped 9.8% to $0.505 in early session trade on heavy volume.

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
researcher filling a vial
April 24 2018
2018 is shaping up to be a crucial year for the company's drug pipeline
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use